A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos [pioglitazone] in Patients With Type 2 Diabetes and NYHA [New York Heart Association] Class II Heart Failure.

Trial Profile

A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos [pioglitazone] in Patients With Type 2 Diabetes and NYHA [New York Heart Association] Class II Heart Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Aleglitazar (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2008 Status changed from in progress to completed, according to Roche site
    • 23 Jan 2008 Updated from Roche site (DMS 23-01-08).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top